Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.

NCT06464614 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer

Interventions

DRUG: Adebrelimab
DRUG: Apatinib
DRUG: Investigator chosen chemotherapy (ICC)
RADIATION: Radiotherapy

Sponsor

The First Affiliated Hospital of Henan University of Science and Technology